Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 72 of 72 matching drugs for EP400 — including drugs targeting any of its 38 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel IGF1R SSL via IGF1R 2
alvocidib, paclitaxel CDK1 SSL via CDK1 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study IGF1R SSL via IGF1R 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study IGF1R SSL via IGF1R 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
selinexor XPO1 SSL via XPO1 yes 2
alisertib AURKA SSL via AURKA 1
alisertib, gemcitabine AURKA SSL via AURKA 1
alvocidib, docetaxel CDK1 SSL via CDK1 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK1 SSL via CDK1 1
arsenic trioxide CCND1 SSL via CCND1 1
arsenic trioxide JUN SSL via JUN 1
arsenic trioxide, radiation therapy CCND1 SSL via CCND1 1
arsenic trioxide, radiation therapy JUN SSL via JUN 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy CCND1 SSL via CCND1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy JUN SSL via JUN 1
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
biopsy, magnetic resonance imaging, radiation therapy, selinexor XPO1 SSL via XPO1 1
biospecimen collection, magnetic resonance imaging, selinexor, temozolomide XPO1 SSL via XPO1 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin CASP3 SSL via CASP3 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin CCND1 SSL via CCND1 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
endoscopic variceal ligation, carvedilol HIF1A SSL via HIF1A 1
entrectinib JAK2 SSL via JAK2 yes 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AURKA SSL via AURKA 1
enzastaurin, lomustine AURKA SSL via AURKA 1
enzastaurin, temozolomide, radiation therapy AURKA SSL via AURKA 1
eras-007, encorafenib, cetuximab, palbociclib CCND1 SSL via CCND1 1
gemcitabine hydrochloride, selinexor, pharmacological study, laboratory biomarker analysis, nab paclitaxel XPO1 SSL via XPO1 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride CFTR SSL via CFTR 1
hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment AURKA SSL via AURKA 1
insulin degludec, insulin glargine IGF1R SSL via IGF1R 1
irbesartan, placebo JUN SSL via JUN 1
laboratory biomarker analysis, linsitinib, pharmacological study, topotecan hydrochloride IGF1R SSL via IGF1R 1
lmb-100, tofacitinib, mesothelin expression JAK2 SSL via JAK2 1
minocycline, placebo, questionnaires CASP3 SSL via CASP3 1
paclitaxel, bryostatin 1 CCND1 SSL via CCND1 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) JAK2 SSL via JAK2 1
pharmacological study, selinexor XPO1 SSL via XPO1 1
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine JUN SSL via JUN 1
ruxolitinib JAK2 SSL via JAK2 yes 1
ruxolitinib, erlotinib JAK2 SSL via JAK2 1
ruxolitinib, radiation, temozolomide JAK2 SSL via JAK2 1
selinexor, acetaminophen XPO1 SSL via XPO1 1
selinexor, temozolomide, generic radiation therapy (rt), selective serotonin receptor (5-ht3) antagonists, olanzapine, salt tablets, anti-diarrheal XPO1 SSL via XPO1 1
semaglutide, insulin aspart, insulin glargine u100 IGF1R SSL via IGF1R 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin CASP3 SSL via CASP3 1
trametinib, ruxolitinib JAK2 SSL via JAK2 1
trametinib, ruxolitinib, retifanlimab JAK2 SSL via JAK2 1
trametinib, vinblastine JUN SSL via JUN 1
vadadustat, darbepoetin alfa HIF1A SSL via HIF1A 1
baricitinib JAK2 SSL via JAK2 yes 0
brigatinib IGF1R SSL via IGF1R yes 0
elexacaftor CFTR SSL via CFTR yes 0
fedratinib JAK2 SSL via JAK2 yes 0
fedratinib hydrochloride JAK2 SSL via JAK2 yes 0
ivacaftor CFTR SSL via CFTR yes 0
lumacaftor CFTR SSL via CFTR yes 0
mecasermin IGF1R SSL via IGF1R yes 0
mecasermin rinfabate IGF1R SSL via IGF1R yes 0
palbociclib CCND1 SSL via CCND1 yes 0
ruxolitinib phosphate JAK2 SSL via JAK2 yes 0
somatropin IGF1R SSL via IGF1R yes 0
tezacaftor CFTR SSL via CFTR yes 0
tofacitinib JAK2 SSL via JAK2 yes 0
tofacitinib citrate JAK2 SSL via JAK2 yes 0
upadacitinib JAK2 SSL via JAK2 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.